Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Full, persistent blockade of central neurokinin-1 (NK1) receptors may be a potential antidepressant mechanism. The selective NK1 antagonist orvepitant (GW823296) was used to test this hypothesis. A preliminary positron emission tomography study in eight male volunteers drove dose selection for two randomized six week studies in patients with major depressive disorder (MDD). Displacement of central [ 11 C]GR205171 binding indicated that oral orvepitant doses of 30–60 mg/day provided >99% receptor occupancy for ≥24 h. Studies 733 and 833 randomized patients with MDD and 17-item Hamilton Depression Rating Scale (HAM-D)≥22 to double-blind treatment with orvepitant 30 mg/day, orvepitant 60 mg/day or placebo (1:1:1). Primary outcome measure was change from baseline in 17-item HAM-D total score at Week 6 analyzed using mixed models repeated measures. Study 733 ( n=328) demonstrated efficacy on the primary endpoint (estimated drug-placebo differences of 30 mg: −2.41, 95% confidence interval (CI) (−4.50 to −0.31) p=0.0245; 60 mg: –2.86, 95% CI (−4.97 to −0.75) p=0.0082). Study 833 ( n=345) did not show significance (estimated drug-placebo differences of 30 mg: −1.67, 95% CI (−3.73 to 0.39) p=0.1122; 60 mg: −0.76, 95% CI (−2.85 to 1.32) p=0.4713). The results support the hypothesis that full, long lasting blockade of central NK1 receptors may be an efficacious mechanism for the treatment of MDD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 1×
“…the Morning Sleep Questionnaire (Roehrs et al., 1984, captured by Clinphone Plc, Nottingham, UK), the Columbia Suicidality Severity Rating Scale (CSSRS, Posner et al., 2011), and the Massachusetts General Hospital Sexual Functioning Questionnaire (MSFQ, Fava et al., 1998; Labbate and Lare, 2001).”
BackgroundRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 2×
“Efficacy and safety assessments conducted at each visit included the HAM-D (17-item using the SIGH-D, Williams, 1988), Clinical Global Impressions - Severity of Illness (CGI-S) and Improvement (CGI-I, Guy, 1976) (Guy, 1976), the Clinical Global Impression of Improvement (CGI-I, 18), the Quick Inventory of Depressive S…”
Wilamowska (2010) · doi:10.1001/archpsyc.1988.01800320058007 · Cited by 2,115 · cited 3×
“Efficacy and safety assessments conducted at each visit included the HAM-D (17-item using the SIGH-D, Williams, 1988), Clinical Global Impressions - Severity of Illness (CGI-S) and Improvement (CGI-I, Guy, 1976) (Guy, 1976), the Clinical Global Impression of Improvement (CGI-I, 18), the Quick…”
MethodConsensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955 · cited 1×
“Consensus nomenclature of PET data was used throughout (Innis et al., 2006).”
MethodECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors
Kramer, M. S., Cutler, N., Feighner, J., Shrivastava, R., Carman, J., Sramek, J. J., Reines, S. A., Liu, G., Snavely, D., Wyatt-Knowles, E., et al. (1998) · Science · doi:10.1126/science.281.5383.1640 · Cited by 1,071 · cited 4×
“The studies reported here and elsewhere (Hargreaves, 2002; Kramer et al., 1998; Ratti et al., 2011) support the hypothesis that NK1 antagonists that provide prolonged and full blockade of NK1 receptors may have significant antidepressant effects in patients with MDD. Based on the PET results, 30…”
BackgroundResultInfluentialAltered nociception, analgesia and aggression in mice lacking the receptor for substance P
Felipe, C. D., Herrero, J. F., O'Brien, J. A., Palmer, J. A., Doyle, C. A., Smith, A. J. H., Laird, J. M. A., Belmonte, C., Cervero, F., & Hunt, S. P. (1998) · Nature · doi:10.1038/32904 · Cited by 755
Depression and suicide attempt as risk factors for incident unprovoked seizures
Hesdorffer, D. C., Hauser, W. A., Olafsson, E., Ludvigsson, P., & Kjartansson, O. (2006) · Annals of Neurology · doi:10.1002/ana.20685 · Cited by 524 · cited 2×
“…as well as epidemiological studies suggesting that depressed populations have a seizure risk several times that in the normal population (Alper et al., 2007; Hesdorffer et al., 2006), all suggest that a causal role for orvepitant appears to be unlikely, though this risk cannot yet be discounted.”
Background
Research works printed but not linked: 8
- Carletti R, 2005, Eur Neuropsychopharmacol, 15, S539
- Chappell P, 2002, Curr Pharm Des, 11, 1529
- Fava M, 2006, J Clin Psychiatry, 67, S14
- First MB, 2002, Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition
- Hargreaves R, 2002, J Clin Psychiatry, 63, S18
- Luthra SK, 1993, J Labelled Comp Radiopharm, 32, 518
- 10.1073/pnas.98.4.1912 · doi:10.1073/pnas.98.4.1912 · Paper page
- 10.1111/j.1755-5949.2008.00038.x · doi:10.1111/j.1755-5949.2008.00038.x
Cited by
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Carvalho, A. F., Heilig, M., Perez, A., Probst, C., & Rehm, J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31775-1 · Cited by 671
Steinhoff, M. S., von Mentzer, B., Geppetti, P., Pothoulakis, C., & Bunnett, N. W. (2014) · Physiological Reviews · doi:10.1152/physrev.00031.2013 · Cited by 628
“A recent clinical trial of the efficacy of the NK1R antagonist orvepitant to treat major depressive disorder supports this proposal (276).”
Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists
Schöppe, J., Ehrenmann, J., Klenk, C., Rucktooa, P., Schütz, M., Dore, A. S., & Plückthun, A. (2018) · Nature Communications · doi:10.1038/s41467-018-07939-8 · Cited by 111
Simon, J. A., Anderson, R. A., Ballantyne, E., Bolognese, J. A., Caetano, C., Joffe, H., Kerr, M., Panay, N., Seitz, C., Seymore, S., et al. (2023) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002138 · Cited by 103
Self-citation
Metadata
- Authors
- Ratti, E., Bettica, P., Alexander, R., Archer, G., Carpenter, D., Evoniuk, G., Gomeni, R., Lawson, E., Lopez, M., Millns, H., Rabiner, E. A., Trist, D., Trower, M., Zamuner, S., Krishnan, R., & Fava, M.
- Affiliations
- GlaxoSmithKline (Italy) (IT)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline Research and Development, Research Triangle Park, NC, USA
- Pharmacometrics, GlaxoSmithKline, Upper Merion, USA
- National University of Singapore (SG)
- Department of Psychiatry, Massachusetts General Hospital, Boston, USA
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2013-03-28
- Volume
- 27
- Issue
- 5
- Pages
- 424-434
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2073690654
- Semantic Scholar
- a7713ffe36f4a8176def2ed3609b2965dfe1feee
- Cited by
- 69
- References
- 38
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 11 · 2023: 9 · 2022: 1 · 2021: 5 · 2020: 5 · 2019: 7 · 2018: 2 · 2017: 8 · 2016: 3 · 2015: 4 · 2014: 4 · 2013: 5
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- neurokinin-1 receptor, major depressive disorder, antidepressant mechanism, receptor occupancy, dose selection, Hamilton Depression Rating Scale
- MeSH terms
- Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Humans, Male, Middle Aged, Piperidines, Radioligand Assay, Bridged Bicyclo Compounds, Heterocyclic, Positron-Emission Tomography, Neurokinin-1 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. https://app.cochat.ai/papers/10.1177/0269881113480990
- The paper
- Ratti, E., Bettica, P., Alexander, R., Archer, G., Carpenter, D., Evoniuk, G., Gomeni, R., Lawson, E., Lopez, M., Millns, H., Rabiner, E. A., Trist, D., Trower, M., Zamuner, S., Krishnan, R., & Fava, M. (2013). Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. Journal of Psychopharmacology. https://doi.org/10.1177/0269881113480990
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.